User:Mr. Ibrahem/Benralizumab

Benralizumab, sold under the brand name Fasenra, is a medication used to treat eosinophilic asthma. It may be used in those not controlled with inhaled corticosteroids and a long-acting beta-agonist. It is given by injection under the skin.

Common side effects include headache and sore throat. Other side effects may include anaphylaxis or hives. Safety in pregnancy is unclear. It is a monoclonal antibody that binds to interleukin-5 receptors (CD125) on eosinophils, resulting in their destruction.

Benralizumab was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom it costs the NHS about £2,000 per dose as of 2021. This amount is about 5,200 USD in the United States.